- Generic name: Orforglipron · Developer code: LY3502970 (Eli Lilly)
- Type: Non-peptide small molecule GLP-1 receptor agonist
- Administration: Oral (once daily) — no injection required
- Phase II peak weight loss: 14.7% at 26 weeks (highest dose, obese cohort)
- ACHIEVE-1 Phase III (36wk): 7.9–9.4% weight loss vs placebo
- Status: Phase III (ACHIEVE programme, 2026)
01 What Is Orforglipron?
Orforglipron (LY3502970) is a once-daily oral non-peptide GLP-1 receptor agonist developed by Eli Lilly. It is the first GLP-1 agonist that is both a small molecule (not a peptide) and fully orally bioavailable without the absorption-enhancer technology required by oral semaglutide (Rybelsus).
All previously approved GLP-1 agonists — semaglutide, tirzepatide, liraglutide, exenatide — are peptide-based and must be administered by subcutaneous injection. Orforglipron's non-peptide structure resists GI peptidase degradation entirely, enabling conventional oral tablet/capsule delivery with consistent pharmacokinetics.
02 Why Oral GLP-1 Bioavailability Is a Research Breakthrough
The GI tract degrades peptides aggressively. Proteases and peptidases in the stomach (pepsin) and small intestine (trypsin, chymotrypsin, elastase) cleave peptide bonds before absorption. The intestinal epithelium presents a further barrier — most peptides cannot cross it without active transport mechanisms. This is why GLP-1 peptide agonists require subcutaneous injection.
Oral semaglutide (Rybelsus) partially addresses this via SNAC — an absorption enhancer that transiently disrupts the gastric epithelium. But SNAC-based delivery is sensitive to food intake, requires large volumes of water, and achieves only ~1% absolute bioavailability. Orforglipron's non-peptide scaffold avoids these limitations entirely, achieving consistent oral exposure comparable to small-molecule drugs.
For research, this distinction matters because:
- It enables oral administration in research models where injection is not feasible or confounds results
- It allows comparison of oral vs injectable GLP-1 pathway activation with matched receptor affinity
- It opens research into GLP-1R engagement in the GI tract itself (local vs systemic effects)
03 Small Molecule GLP-1R Agonism Mechanism
Orforglipron is an allosteric activator of GLP-1R — it binds within the transmembrane domain of the receptor rather than at the peptide binding site used by GLP-1, semaglutide, or tirzepatide. Despite this different binding site, orforglipron produces the same downstream signalling cascade: Gs protein coupling → cAMP elevation → PKA activation → insulin secretion and appetite suppression.
Key pharmacological properties:
- Oral bioavailability: Substantially higher than peptide GLP-1 agonists; food-independent absorption
- Half-life: Approximately 24 hours (enables once-daily dosing)
- GLP-1R selectivity: Selective for GLP-1R; does not activate GIPR or GlucagonR (unlike tirzepatide/retatrutide)
- Non-peptide structure: Resistant to GI peptidase degradation; stable at room temperature
04 ACHIEVE Trial Programme Data
- Obese cohort (non-T2D): up to −14.7% mean weight loss at highest dose
- T2D cohort: −1.3% to −2.1% HbA1c reduction; −8.3% to −10.1% body weight
- All doses statistically significant vs placebo across both cohorts
- Mean weight loss: 7.9% to 9.4% depending on dose vs placebo
- Population: adults with obesity or overweight with weight-related comorbidities
- Further ACHIEVE trials ongoing for T2D and cardiovascular endpoints
Phase III weight loss (7.9–9.4% at 36 weeks) is lower than Phase II data (14.7%) — consistent with broader study populations in Phase III versus optimised Phase II cohorts. Phase III trials typically show more conservative results due to less selected populations, different dose titration schedules, and longer run-in periods.
05 Orforglipron vs Injectable GLP-1 Agonists
| Property | Orforglipron | Semaglutide 2.4mg | Tirzepatide 15mg |
|---|---|---|---|
| Format | Oral (once daily) | Weekly injection | Weekly injection |
| Peptide/Small molecule | Small molecule | Peptide | Peptide |
| Receptor targets | GLP-1R only | GLP-1R only | GLP-1R + GIPR |
| Room temp stable | Yes | No (refrigerate) | No (refrigerate) |
| Peak Ph III weight loss | ~9.4% (36wk) | ~15% (68wk) | ~20.9% (72wk) |
| Approval status (2026) | Phase III | Approved | Approved |
Orforglipron's weight loss data is more modest than injectable GLP-1 agonists in Phase III — but trials are shorter and dose titration may not be fully optimised. The critical advantage is oral delivery: for research models where injection is impractical, orforglipron provides equivalent GLP-1R activation without route-of-administration confounders.
06 Frequently Asked Questions
What is Orforglipron?
Orforglipron (LY3502970) is a non-peptide, small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike semaglutide or tirzepatide — which are peptide-based and require injection — orforglipron is a chemically synthesized small molecule with demonstrated oral bioavailability. It activates GLP-1R with similar downstream effects to peptide GLP-1 agonists (appetite suppression, insulin secretion, glycaemic control) without the need for reconstitution or injection.
Why does oral bioavailability matter for GLP-1 research?
Peptide-based GLP-1 agonists (semaglutide, tirzepatide, retatrutide) are degraded by gastrointestinal peptidases and acids before reaching systemic circulation — which is why they require subcutaneous injection. Orforglipron's non-peptide structure bypasses this limitation, achieving oral bioavailability that peptides cannot. This opens research models for oral metabolic intervention and enables comparison of oral vs injectable GLP-1 pathway activation without confounding injection-route effects.
What weight loss does Orforglipron produce?
Phase III ACHIEVE-1 trial data (36 weeks) showed orforglipron produced mean body weight reductions of approximately 7.9% to 9.4% depending on dose, versus placebo. A separate Phase II trial (26 weeks) showed up to 14.7% mean weight loss at the highest dose — with HbA1c reductions of −1.3 to −2.1 percentage points in a T2D population.
How does Orforglipron differ from Rybelsus (oral semaglutide)?
Rybelsus is oral semaglutide — it uses a SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) absorption enhancer to enable gastric absorption. It still requires fasting administration, large amounts of water, and has variable absorption (bioavailability ~1%). Orforglipron is a small molecule that does not rely on an absorption enhancer — it has intrinsically superior oral bioavailability and can be taken without fasting restrictions.
What stage of development is Orforglipron in?
As of April 2026, orforglipron is in Phase III development (ACHIEVE programme) for obesity and type 2 diabetes. Eli Lilly has multiple ongoing Phase III trials. Phase II data was published in NEJM Evidence in 2023. No regulatory approval has been granted as of this writing.
Related research: